^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MIR3651 (MicroRNA 3651)

i
Other names: MIR3651, MicroRNA 3651, Hsa-Mir-3651, Hsa-MiR-3651, MIR3651
4ms
GOLM1-induced Vascular Permeability and Angiogenesis in Hepatocellular Carcinoma through Modulation of Cancer Cell-derived Exosomal microRNAs. (PubMed, Curr Cancer Drug Targets)
Our findings suggest that, under the control of GOLM1, HCC cell-derived exosomal miR-4449 and miR-3651 increase angiogenesis and vascular permeability by targeting KEAP1 and ZO-1, highlighting the potential of exosomal miRNAs as promising therapeutic targets for HCC.
Journal
|
EGFR (Epidermal growth factor receptor) • KEAP1 (Kelch Like ECH Associated Protein 1) • GOLM1 (Golgi Membrane Protein 1) • MIR3651 (MicroRNA 3651) • TJP1 (Tight Junction Protein 1)
6ms
Non-viral HCC miRNA profiling reveals miR-1972 as a potential positive prognostic marker. (PubMed, Noncoding RNA Res)
miRNA-1972 is a strong prognostic marker in non-viral HCC. Dysregulation of several other miRNAs relates to pathological variables such as amount of stroma within tumor, microvascular invasion and micronodularity.
Journal
|
TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR3651 (MicroRNA 3651) • MIR1972-1 (MicroRNA 1972-1) • MIR486-1 (MicroRNA 486-1)
|
TP53 mutation
7ms
Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in lung adenocarcinoma. (PubMed, Lung Cancer)
This study provides a systematic in silico framework for identifying LUAD associated miRNAs. The discovery of five novel miRNAs highlights their potential as diagnostic biomarkers and therapeutic targets, offering valuable insights for experimental and clinical investigations in LUAD.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MIR18A (MicroRNA 18a) • MIR3651 (MicroRNA 3651) • MIR122 (MicroRNA 122)
almost3years
Integration of Human and Viral miRNAs in Epstein-Barr Virus-Associated Tumors and Implications for Drug Repurposing. (PubMed, OMICS)
Importantly, we used the DEMs during EBV latent infection types I, II, and III to identify the candidate drugs for repurposing: Glyburide, Levodopa, Nateglinide, and Stiripentol, among others. To the best of our knowledge, this is the first integrative analyses that identified DEmiRs and DEMs as potential therapeutic targets and predicted drugs as potential candidates for repurposing against EBV-related tumors.
Journal
|
MIR3651 (MicroRNA 3651) • MIR98 (MicroRNA 98)
over3years
miR-3651 Participates in the Growth Cycle of Hepatocellular Carcinoma Cells and Promotes the Malignant Metastasis via the PI3K/AKT/mTOR Signalling Pathway. (PubMed, J Oncol)
Moreover, HepG2 presented notably downregulated autophagy-associated proteins, and the increase of miR-3651 further suppressed the autophagy process, but with the intervention of BEZ235, the impacts of miR-3651 were completely reversed. miR-3651 intensifies the growth and invasion of HCC cells through activating the PI3K/AKT/mTOR signalling pathway, which is probably a breakthrough in the future diagnosis and therapy of HCC.
Journal
|
MIR3651 (MicroRNA 3651)
|
miR-3651 expression
|
dactolisib (RTB101)
almost4years
Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3. (PubMed, Breast Cancer)
The current study revealed that hsa-miR-3651 is a predictor of LC in early breast cancer via its putative target protein FRMD3. Since microRNAs interfere in multiple pathways, the results of this hypothesis generating study may contribute to the development of tailored therapies for breast cancer in the future.
Journal
|
MIR3651 (MicroRNA 3651)
over5years
miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma. (PubMed, J Ovarian Res)
The detected 99 miRNAs out of 2549 miRNAs might be used in the clinic as new biological indicators in the diagnosis and follow up of epithelial ovarian cancer with complementary studies. The miRNA expression profiles were identified to be statistically significant in the evaluation of ovarian cancer etiology, BRCA1 mutation status, and ovarian cancer risk in accordance with the obtained data. There is a need for validation of the miRNAs which were particularly detected between monozygotic twins and its association with ovarian cancer was emphasized in our study in wider cohorts including ovarian cancer patients, and healthy individuals.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • MIR3651 (MicroRNA 3651) • MIR664A (MicroRNA 664a)
|
BRCA1 mutation